NCT05655767

Brief Summary

Rationale: Aortic diameter is currently used as a gold standard in international guidelines for prediction of aorta pathology (aortic aneurysm and aortic dissection). However, aortic diameter has proven to be insufficiently accurate for making decisions about well-timed preventive interventions. The LANDMARC study will take place in line with the FIBAA-bank ('Correlatie tussen cardiovasculaire FIBroseringsgraad en Aorta elongatie, dilatatie en Atria dilatatie (FIBAA-bank): een biobank \& databank onderzoek met focus op aorta en atria' (METC-number 2022-3164)), and aims to reveal the undiscovered relationship between WSS (wall shear stress) values and aortic strain. In combination with data from the FIBAA-bank, the LANDMARC study will provide more accurate information for future risk stratification models for cardiovascular pathology (with focus on aortic disease). Objectives: Primary objective: indication of the association between WSS (peak WSS and WSS gradient) (through 4D-flow MR and CT) and aortic strain. Secondary objective: indication of the association between (hemo)dynamic processes within the body (aortic elongation/aortic strain) and (patho-)physiological changes (degree of cardiovascular tissue fibrosis).

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
65

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Dec 2022

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 22, 2022

Completed
23 days until next milestone

Study Start

First participant enrolled

December 15, 2022

Completed
4 days until next milestone

First Posted

Study publicly available on registry

December 19, 2022

Completed
12 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 15, 2023

Completed
1.1 years until next milestone

Study Completion

Last participant's last visit for all outcomes

January 15, 2025

Completed
Last Updated

December 19, 2022

Status Verified

November 1, 2022

Enrollment Period

1 year

First QC Date

November 22, 2022

Last Update Submit

December 16, 2022

Conditions

Outcome Measures

Primary Outcomes (1)

  • Indication of the association between WSS (peak WSS and WSS gradient) (through 4D-flow MR and CT) and aortic strain.

    Previous research described the importance of aortic strain for the prediction of aortic disease. By linking this information to information that can be obtained via advanced imaging techniques, future predictions about aortic disease can be made more easily and will be more accurate.

    Until 12 months postoperative

Secondary Outcomes (1)

  • Indication of the association between (hemo)dynamic processes within the body (aortic elongation/aortic strain) and (patho-)physiological changes (degree of cardiovascular tissue fibrosis).

    Until 12 months postoperative

Interventions

4D-flow MR and CT-scan after cardiac surgery (until 12 months afterwards), for the purpose of obtaining more precise data on (hemo)dynamic processes within the cardiovascular system, in combination with data extraction from the established biobank and databank (FIBAA-bank).

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

The study population of the LANDMARC study will consist of patients who underwent open heart surgery and have participated in FIBAA-bank.

You may qualify if:

  • years and older
  • Able to understand the trial and provide informed consent
  • Patients who have participated in the FIBAA-bank

You may not qualify if:

  • Patients with abnormal congenital cardiothoracic anatomy, with exception of presence of a bicuspid aortic valve
  • Patients with history of chemotherapy, or radiotherapy within thoracic region
  • Patients with an age \>80 years
  • Patients with a weight \>120 kg
  • Patients with a contra-indication for MRI according to the MUMC+ ODIN protocol nr. 004952
  • Patients with impaired renal function (GFR \<30)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

MaastrichtUMC

Maastricht, Limburg, 6229 HX, Netherlands

Location

MeSH Terms

Conditions

Aortic DiseasesAortic AneurysmAortic DissectionAortic Aneurysm, Thoracic

Condition Hierarchy (Ancestors)

Vascular DiseasesCardiovascular DiseasesAneurysmDissection, Blood VesselAcute Aortic Syndrome

Central Study Contacts

Sophie ML van de Walle, PhD student

CONTACT

Elham Bidar, MD, PhD

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 22, 2022

First Posted

December 19, 2022

Study Start

December 15, 2022

Primary Completion

December 15, 2023

Study Completion

January 15, 2025

Last Updated

December 19, 2022

Record last verified: 2022-11

Locations